tallcandle
MemberOne
- Registrato
- 16/1/03
- Messaggi
- 28.170
- Punti reazioni
- 1.761
Target under review
Studi Societari - Borsa Italiana
According to management, 3Q23 has been showing some signs of recovery with selling volumes up by some 20% at an average price of €260/kg. This recovery comes mainly from Europe and US where demand for functional make-up has been strongly growing and to a much less extend from China. We expect this recovery path to continue in the last quarter and we based our turnover downward revision on this assumption. According to management, new demand from functional demand from Europe and US together with a much clear rebound from China will lead to robust growth and marginality in FY24, which might be Arterrra’s best year ever
________________________
Resta, a pagina 6, evidente la sottovalutazione: il multiplo EV/Ebitda si aggira sui 10x/12x.
Questo significa che SE nel 2024 verrà confermato il ritorno della domanda cinese, la sottovalutazione sarà ancora più evidente di oggi.
Studi Societari - Borsa Italiana
According to management, 3Q23 has been showing some signs of recovery with selling volumes up by some 20% at an average price of €260/kg. This recovery comes mainly from Europe and US where demand for functional make-up has been strongly growing and to a much less extend from China. We expect this recovery path to continue in the last quarter and we based our turnover downward revision on this assumption. According to management, new demand from functional demand from Europe and US together with a much clear rebound from China will lead to robust growth and marginality in FY24, which might be Arterrra’s best year ever
________________________
Resta, a pagina 6, evidente la sottovalutazione: il multiplo EV/Ebitda si aggira sui 10x/12x.
Questo significa che SE nel 2024 verrà confermato il ritorno della domanda cinese, la sottovalutazione sarà ancora più evidente di oggi.